Zymeworks Presents ZW191 Clinical Data at ESMO 2026
Zymeworks presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha-targeting antibody-drug conjugate, ADC, at the European Society for Medical Oncology, ESMO, Gynaecological Cancers Congress 2026. Key highlights include: ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRalpha expression level; Confirmed objective response rate of 78.6% in FRalpha-positive platinum-resistant ovarian cancer patients and 47.4% in FRalpha-negative patients across all dose levels studied; Median duration of response was not reached at the time of data cutoff, and median progression-free survival was 7.6 months across ovarian and endometrial cancer cohorts; Patient recruitment in dose optimization cohorts completed, with favorable tolerability profile and broad therapeutic window supporting continued clinical development
